Androgen receptors beyond prostate cancer: an old marker as a new target

por Munoz, Javier, Wheler, Jennifer J., Kurzrock, Razelle
Publicado 2014

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors

por Wheler, Jennifer, Mutch, David, Lager, Joanne, Castell, Christelle, Liu, Li, Jiang, Jason, Traynor, Anne M.
Publicado 2017

Multiple gene aberrations and breast cancer: lessons from super-responders

por Wheler, Jennifer J., Atkins, Johnique T., Janku, Filip, Moulder, Stacy L., Yelensky, Roman, Stephens, Philip J., Kurzrock, Razelle
Publicado 2015

Challenges and perspective of drug repurposing strategies in early phase clinical trials

por Kato, Shumei, Moulder, Stacy L., Ueno, Naoto T., Wheler, Jennifer J., Meric-Bernstam, Funda, Kurzrock, Razelle, Janku, Filip
Publicado 2015

A pilot study of temsirolimus and body composition

por Veasey-Rodrigues, Heloisa, Parsons, Henrique A., Janku, Filip, Naing, Aung, Wheler, Jennifer J., Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicado 2013

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

por Naing, Aung, Fu, Siqing, Zinner, Ralph G., Wheler, Jennifer J., Hong, David S., Arakawa, Kazuhito, Falchook, Gerald S., Kurzrock, Razelle
Publicado 2013

Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study

por Chawla, Anita, Janku, Filip, Wheler, Jennifer J., Miller, Vincent A., Ryan, Jason, Anhorn, Rachel, Zhou, Zhou, Signorovitch, James
Publicado 2018

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer

por Tsigelny, Igor F., Wheler, Jennifer J., Greenberg, Jerry P., Kouznetsova, Valentina L., Stewart, David J., Bazhenova, Lyudmila, Kurzrock, Razelle
Publicado 2015

PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells

por Rivera-Del Valle, Nilsa, Gao, Shan, Miller, Claudia P., Fulbright, Joy, Gonzales, Carolina, Sirisawad, Mint, Steggerda, Susanne, Wheler, Jennifer, Balasubramanian, Sriram, Chandra, Joya
Publicado 2010

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

por Wheler, Jennifer, Yelensky, Roman, Falchook, Gerald, Kim, Kevin B, Hwu, Patrick, Tsimberidou, Apostolia M, Stephens, Philip J, Hong, David, Cronin, Maureen T, Kurzrock, Razelle
Publicado 2015

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

por Piha-Paul, Sarina A., Wheler, Jennifer J., Fu, Siqing, Levenback, Charles, Lu, Karen, Falchook, Gerald S., Naing, Aung, Hong, David S., Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicado 2014

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

por Wheler, Jennifer J., Atkins, Johnique T., Janku, Filip, Moulder, Stacy L., Stephens, Philip J., Yelensky, Roman, Valero, Vicente, Miller, Vincent, Kurzrock, Razelle, Meric-Bernstam, Funda
Publicado 2016

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

por Sharman, Jeffrey P., Wheler, Jennifer J., Einhorn, Lawrence, Dowlati, Afshin, Shapiro, Geoffrey I., Hilton, John, Burke, John M., Siddiqi, Tanya, Whiting, Nancy, Jalal, Shadia I.
Publicado 2019

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

por Hou, Ming-Mo, Liu, Xiaochun, Wheler, Jennifer, Naing, Aung, Hong, David, Coleman, Robert L., Tsimberidou, Apostolia, Janku, Filip, Zinner, Ralph, Lu, Karen, Kurzrock, Razelle, Fu, Siqing
Publicado 2014

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses

por Wheler, Jennifer, Hong, David, Swisher, Stephen G., Falchook, Gerald, Tsimberidou, Apostolia M., Helgason, Thorunn, Naing, Aung, Stephen, Bettzy, Janku, Filip, Stephens, Philip J., Yelensky, Roman, Kurzrock, Razelle
Publicado 2013

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors

por Naing, Aung, Reuben, James M., Camacho, Luis H., Gao, Hui, Lee, Bang-Ning, Cohen, Evan N., Verschraegen, Claire, Stephen, Saneese, Aaron, Joann, Hong, David, Wheler, Jennifer, Kurzrock, Razelle
Publicado 2011

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

por Said, Rabih, Hong, David S., Warneke, Carla L., Lee, J. Jack, Wheler, Jennifer J., Janku, Filip, Naing, Aung, Falchook, Gerald S., Fu, Siqing, Piha-Paul, Sarina, Tsimberidou, Apostolia M., Kurzrock, Razelle
Publicado 2013

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase...

por Wheler, Jennifer, Falchook, Gerald, Tsimberidou, Apostolia M., Hong, David, Naing, Aung, Piha-Paul, Sarina, Chen, Su S., Heymach, John, Fu, Siqing, Stephen, Bettzy, Fok, Jansina Y., Janku, Filip, Kurzrock, Razelle
Publicado 2013

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

por Falchook, Gerald S., Naing, Aung, Wheler, Jennifer J., Tsimberidou, Apostolia M., Zinner, Ralph, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Janku, Filip, Hess, Kenneth R., Bastida, Christel, Kurzrock, Razelle
Publicado 2014

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer

por Falchook, Gerald S., Naing, Aung, Hong, David S., Zinner, Ralph, Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Morgan-Linnell, Sonia K., Jiang, Yunfang, Bastida, Christel, Wheler, Jennifer J., Kurzrock, Razelle
Publicado 2013